HORSHAM, PA — Exegenesis Bio will supply its muscle-targeting AAV delivery technology to Modalis Therapeutics Corp. (TOKYO: 4883) under a research and licensing agreement aimed at advancing an experimental Duchenne …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.